Senhwa Biosciences, Inc.

6492

TW0006492002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
41.7 ^TWD	+0.85%		+0.60%	-18.07%

05-15	Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-20	Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	03-20	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19	01-05	CI
Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	12-26	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19	11-09	CI
Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	23-10-19	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Senhwa Biosciences Receives Taiwan Fda Ind Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe Covid-19	23-04-28	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer	22-10-31	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC	22-06-06	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting	22-03-28	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
US FDA Grants Fast Track Designation to Senhwa Biosciences' Cancer Drug	22-01-26	MT
Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations	22-01-25	CI
Us Food and Drug Administration Grants Orphan Drug Designation to Senhwa Biosciences, Inc. for Silmitasertib, A Highly Selective Inhibitor of Casein Kinase 2	22-01-20	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference	21-10-20	CI
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference	21-09-27	CI

Chart Senhwa Biosciences, Inc.

Duration

Period

More charts

Senhwa Biosciences, Inc. is a Taiwan-based company principally engaged in the research and development of anti-cancer new drugs and special drug substances. The Company's main development projects include the CX-5461, for the treatment of hematologic cancers and breast cancers, as well as the CX-4945, for the treatment of cholangiocarcinoma. The Company has not generated any revenues yet.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SENHWA BIOSCIENCES, INC.	-18.07%	114M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B